Half-year report · Q2
3341.TEDINET S100URMJ
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥175.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥340.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥166.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥423m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥3.4bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥772m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥9.4bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.4bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥762m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.4bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥43m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.7bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥43m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥1.7bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥204.1bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥195.1bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥193.5bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥146.3bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥136.7bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥57.9bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥58.4bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥57.9bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥26.4bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥26.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥26.4bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥22.2bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥20.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥11.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥6.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥13.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥8.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥4.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥5.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-1.44 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.35 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥58.44 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 28.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.9% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.9% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥6.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥6.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥4.2bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥156.6bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥156.6bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥4.5bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥6.0bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.9bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥122m |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥766m |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥19.6bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥13.1bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.5bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥652m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥182.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥175.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥4.6bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥6.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥6.7bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥3.5bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥147.6bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥147.6bn |
| jpcrp040300-q2r_E05422-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥6.0bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥4.9bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥4.9bn |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥14m |
| jpcrp040300-q2r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥698m |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥20.5bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥6.7bn |
| jpcrp040300-q2r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥167m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥173.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥166.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥6.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥6.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 520
| Item | Context | Value | Unit |
|---|---|---|---|
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 1750000000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | -42000000 | JPY |
| Income before income taxes | Prior1YTDDuration | 3378000000 | JPY |
| Income before income taxes | CurrentYTDDuration | 762000000 | JPY |
| Depreciation and amortization ope cf | Prior1YTDDuration | 3212000000 | JPY |
| Depreciation and amortization ope cf | CurrentYTDDuration | 3608000000 | JPY |
| Impairment loss ope cf | Prior1YTDDuration | 71000000 | JPY |
| Impairment loss ope cf | CurrentYTDDuration | 69000000 | JPY |
| Compensation income ope cf | Prior1YTDDuration | -32000000 | JPY |
| Compensation income ope cf | CurrentYTDDuration | -33000000 | JPY |
| Amortization of goodwill ope cf | Prior1YTDDuration | 939000000 | JPY |
| Amortization of goodwill ope cf | CurrentYTDDuration | 950000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | Prior1YTDDuration | -0 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | CurrentYTDDuration | 39000000 | JPY |
| Increase decrease in provision for bonuses ope cf | Prior1YTDDuration | 550000000 | JPY |
| Increase decrease in provision for bonuses ope cf | CurrentYTDDuration | 324000000 | JPY |
| Increase decrease in provision for directors bonuses ope cf | Prior1YTDDuration | -68000000 | JPY |
| Increase decrease in provision for directors bonuses ope cf | CurrentYTDDuration | -63000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | Prior1YTDDuration | 111000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | CurrentYTDDuration | 96000000 | JPY |
| Increase decrease in provision for directors retirement benefits ope cf | Prior1YTDDuration | 7000000 | JPY |
| Increase decrease in provision for directors retirement benefits ope cf | CurrentYTDDuration | -7000000 | JPY |
| Interest and dividends income ope cf | Prior1YTDDuration | -0 | JPY |
| Interest and dividends income ope cf | CurrentYTDDuration | -34000000 | JPY |
| Interest expenses ope cf | Prior1YTDDuration | 178000000 | JPY |
| Interest expenses ope cf | CurrentYTDDuration | 212000000 | JPY |
| Loss gain on sales of noncurrent assets ope cf | Prior1YTDDuration | -50000000 | JPY |
| Loss gain on sales of noncurrent assets ope cf | CurrentYTDDuration | -11000000 | JPY |
| Loss gain on sales of investment securities ope cf | Prior1YTDDuration | － | JPY |
| Loss gain on sales of investment securities ope cf | CurrentYTDDuration | -14000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YTDDuration | 1218000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYTDDuration | 911000000 | JPY |
| Decrease increase in inventories ope cf | Prior1YTDDuration | -5671000000 | JPY |
| Decrease increase in inventories ope cf | CurrentYTDDuration | -9315000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YTDDuration | 9844000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYTDDuration | 7556000000 | JPY |
| Other net ope cf | Prior1YTDDuration | 543000000 | JPY |
| Other net ope cf | CurrentYTDDuration | -1603000000 | JPY |
| Subtotal ope cf | Prior1YTDDuration | 14232000000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | 3448000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YTDDuration | 0 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 1000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -83000000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -151000000 | JPY |
| Income taxes paid ope cf | Prior1YTDDuration | -2248000000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -1732000000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 11900000000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 1565000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -3526000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -3804000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |